Page last updated: 2024-12-06

whr-1142a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID47509
CHEMBL ID1490570
SCHEMBL ID637088
MeSH IDM0075215

Synonyms (44)

Synonym
lidaral
lidamidine hydrochloride
whr-1142a
lidamidine hydrochloride (usan)
65009-35-0
D02407
smr000431510
MLS000768111
1-(methylamidino)-3-(2,6-xylyl)urea monohydrochloride
urea, n-(2,6-dimethylphenyl)-n'-(imino(methylamino)methyl)-, monohydrochloride
lidamidine hydrochloride [usan]
einecs 265-307-6
lidarral
urea, 1-(2,6-xylyl)-3-methylamidino-, hydrochloride
1-(2,6-dimethylphenyl)-3-(imino(methylamino)methyl)uronium chloride
smodin
1-(2,6-dimethylphenyl)-3-methylamidinourea hydrochloride
1-(2,6-dimethylphenyl)-3-(n'-methylcarbamimidoyl)urea hydrochloride
einecs 266-299-7
66283-88-3
n-(2,6-xylyl)-n'-(imino(methylamino)methyl)urea hydrochloride
urea, n-(2,6-dimethylphenyl)-n'-(imino(methylamino)methyl)-, hydrochloride
CHEMBL1490570
unii-3q1q4qjv3v
lidamidine hcl
3q1q4qjv3v ,
lidamidine hydrochloride [mart.]
lidamidine hydrochloride [who-dd]
lidamidine hydrochloride [mi]
SCHEMBL637088
1-(2',6'-dimethylphenyl)-3-methylamidinourea hydrochloride
INMBONSHXVMDSX-UHFFFAOYSA-N
n-(2,6-xylyl)-n'-[imino(methylamino)methyl]urea hydrochloride
AKOS030517260
1-(2,6-dimethylphenyl)-3-[imino(methylamino)methyl]uronium chloride
2-hydroxymethyl-2-nitro-propane-1,3-diol
n'-(2,6-dimethylphenyl)-n-(n-methylcarbamimidoyl)carbamimidic acid--hydrogen chloride (1/1)
DTXSID10983557
1-(2,6-dimethylphenyl)-3-(n'-methylcarbamimidoyl)urea;hydrochloride
Q27257888
urea,n-(2,6-dimethylphenyl)-n'-[imino(methylamino)methyl]-,hydrochloride
lidamidine (hydrochloride)
CS-0088765
HY-107358A
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pyruvate kinase PKM isoform aHomo sapiens (human)Potency7.07950.04017.459031.6228AID1631; AID1634
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency16.36010.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]